Xbrane Biopharma says Xdivane melanoma pivotal trial reaches full recruitment of about 340 patients
Xbrane reported full recruitment in its pivotal clinical trial for Xdivane, a biosimilar candidate to Opdivo (nivolumab). No results have been presented; the program now moves toward generating data for future regulatory submissions. The milestone advances Xdivane toward potential commercialization, with Intas leading